Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Lorente, L. (Leonardo) | - |
dc.creator | Martin, M.M. (María M.) | - |
dc.creator | Ramos, L. (Luis) | - |
dc.creator | Argueso, M. (Mónica) | - |
dc.creator | Caceres, J.J. (Juan J.) | - |
dc.creator | Sole-Violan, J. (Jordi) | - |
dc.creator | Jimenez, A. (Alejandro) | - |
dc.creator | Borreguero-Leon, J.M. (Juan María) | - |
dc.creator | González-Rivero, A. (Agustín F.) | - |
dc.creator | Orbe, J. (Josune) | - |
dc.creator | Rodriguez, J.A. (José Antonio) | - |
dc.creator | Paramo, J.A. (José Antonio) | - |
dc.date.accessioned | 2022-03-22T08:13:17Z | - |
dc.date.available | 2022-03-22T08:13:17Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Lorente, L. (Leonardo); Martin, M.M. (María M.); Ramos, L. (Luis); et al. "High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients". BMC Neurology. 19 (167), 2019, 2019 | es |
dc.identifier.issn | 1471-2377 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63272 | - |
dc.description.abstract | Background: Higher circulating levels of tissue inhibitor of matrix metalloproteinases (TIMP)-1 early after ischemic stroke have been associated with lower survival. The objectives of this study were to determine serum TIMP-1 levels during the first week of a severe cerebral infarction in surviving and non-surviving patients, and whether those levels during the first week could be used as a mortality biomarker for these patients. Methods: We included patients with severe malignant middle cerebral artery infarction (MMCAI) defined as computer tomography showing ischaemic changes in more than 50% of the middle cerebral artery territory and Glasgow Coma Scale (GCS) ≤ 8. We measured serum levels of matrix metalloproteinases (MMP)-9 and TIMP-1. End-point study was 30-day mortality. Results: We found higher TIMP-1 concentrations at days 1 (p < 0.001), 4 (p = 0.001), and 8 (p = 0.03) of MMCAI in nonurviving (n = 34) than in surviving (n = 34) patients. We found lower serum MMP-9 concentrations at day 1 (p = 0.03) of MMCAI and no significant differences at days 4 and 8. ROC curve analysis of TIMP-1 concentrations performed at days 1, 4, and 8 of MMCAI showed an area under curve to predict 30-day mortality of 81% (p < 0.001), 80% (p < 0.001) and 72% (p = 0.07) respectively. Conclusions: The new findings of our study were that non-surviving MMCAI patients showed higher serum TIMP-1 levels during the first week of MMCAI that surviving patients, and those levels during the first week of MMCAI could be used as mortality biomarkers. | es_ES |
dc.description.sponsorship | This study was supported by a grant (OA18/011) from Fundación DISA a la Investigación Médica 2017 (Santa Cruz de Tenerife. Spain). Funding did not influence in the study design, the collection, analysis, and interpretation of data, the manuscript writing, and the decision to submit it for publication | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Science and Business Media LLC | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | TIMP-1 | es_ES |
dc.subject | Ischemic stroke | es_ES |
dc.subject | Patients | es_ES |
dc.subject | Mortality | es_ES |
dc.subject | Prognosis | es_ES |
dc.title | High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | es_ES |
dc.identifier.doi | 10.1186/s12883-019-1401-8 | - |
dadun.citation.number | 167 | es_ES |
dadun.citation.publicationName | BMC Neurology | es_ES |
dadun.citation.startingPage | 2019 | es_ES |
dadun.citation.volume | 19 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.